Original Article

Generalisability of Results from UK Biobank: Comparison With a Pooling of 18 Cohort Studies

G. David Batty^{a,b} (<u>david.batty@ucl.ac.uk</u>; ORCID: 0000-0003-1822-5753) Catharine R. Gale^{c,d} (<u>crg@mrc.soton.ac.uk</u>; ORCID: 0000-0002-3361-8638) Mika Kivimäki^a (<u>m.kivimaki@ucl.ac.uk</u>; ORCID: 0000-0002-4699-5627) Ian J. Deary^d (<u>ian.deary@ed.ac.uk</u>; ORCID: 0000-0002-1733-263X) Steven Bell^{e,f} (scb81@medschl.cam.ac.uk; ORCID: 0000-0001-6774-3149)

Manuscript statistics: 2726 words (plus 296 abstract), 58 references, 1 table, 3 figures, 2 supplemental tables, and 4 supplemental figures

Correspondence: David Batty, Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, UK, WC1E 6BT. E. david.batty@ucl.ac.uk

Acknowledgements: GDB is supported by the UK Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1); MK by the UK Medical Research Council (MR/R024227), US National Institute on Aging (NIH), US (R01AG056477), NordForsk, and Academy of Finland (311492); CRG by the UK Medical Research Council (MRC_MC_UU_12011/2 and MRC_MC_UP_A620_1015); and SB by the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (RG/13/13/30194), and NIHR Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust. There was no direct financial or material support for the work reported in the manuscript.

Access to data: Data from The UK Biobank (http://www.ukbiobank.ac.uk/), and The Health Surveys for England and The Scottish Health Surveys (https://data-archive.ac.uk/) are available to researchers upon application. Part of this research has been conducted using the UK Biobank Resource under Application 10279.

Conflict of interest: All authors are registered and enthusiastic users of UK Biobank. Ian Deary had a role in the design of the cognitive function battery.

Contributions: GDB generated the idea for the present paper, formulated an analytical plan, and wrote the manuscript; CRG (UK Biobank) and SB (HSE-SHS) formulated an analytical plan and carried out the data analyses; and SB prepared the figures. All authors commented on an earlier version of the manuscript.

^aDepartment of Epidemiology and Public Health, University College London, UK

^bSchool of Biological and Population Health Sciences, Oregon State University, USA

^cMRC Lifecourse Epidemiology Unit, University of Southampton, UK

^dLothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK

^eCardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK

^fNational Institute for Health Research Blood and Transplant Unit in Donor Health and Genomics at the University of Cambridge, UK

Abstract

Background: The UK Biobank cohort study has become a much-utilised and influential scientific resource. With a primary goal of understanding disease aetiology, the low response to the original survey of 5.5% has, however, led to debate as to the generalisability of these findings. We therefore compared risk factor–disease estimations in UK Biobank with those from 18 nationally representative studies with conventional response rates.

Methods: We used individual-level baseline data from UK Biobank (N=502,655) and a pooling of data from the Health Surveys for England (HSE) and the Scottish Health Surveys (SHS), comprising 18 studies and 89,895 individuals (mean response rate 68%). Both study populations were aged 40-69 years at study induction and linked to national cause-specific mortality registries.

Findings: Despite a typically more favourable risk factor profile and lower mortality rates in UK Biobank participants relative to the HSE-SHS consortium, risk factors—endpoints associations were directionally consistent between studies, albeit with some heterogeneity in magnitude. For instance, for cardiovascular disease mortality, the age- and sex-adjusted hazard ratio (95% confidence interval) for ever having smoked cigarettes (versus never) was 2.04 (1.87, 2.24) in UK Biobank and 1.99 (1.78, 2.23) in HSE-SHS, yielding a ratio of hazard ratios close to unity (1.02, 0.88, 1.19; p-value 0.76). For hypertension (versus none), corresponding results were again in same direction but with a lower effect size in UK Biobank (1.89; 1.69, 2.11) than in HSE-SHS (2.56; 2.20, 2.98), producing a ratio of hazard ratios below unity (0.74; 0.62, 0.89; p-value 0.001). A similar pattern of observations were made for risk factors (smoking, obesity, educational attainment, and physical stature) in relation to different cancer presentations and suicide whereby the ratios of hazard ratios ranged from 0.57 (0.40, 0.81) and 1.07 (0.42, 2.74).

Interpretation: Despite a low response rate, aetiological findings from UK Biobank appear to be generalisable to England and Scotland.

Research in context

Evidence before this study

The primary objective of UK Biobank is to identify risk factors for chronic diseases and injuries of public health importance. That the baseline response rate of 5.5% was an order of magnitude lower than comparable studies has raised concerns about the generalisability of its findings.

Added value of this study

For the first time to our knowledge, we directly compared risk factor-health outcome associations in UK Biobank with a pooling of individual-level data from 18 nationally-sampled cohort studies drawn from England and Scotland, all of which have conventional response rates (mean 68%). Risk factor-mortality associations were directionally the same as comparator studies with some heterogeneity in magnitude.

Implications of all the available evidence

Despite more favourable levels of baseline characteristics and disease-specific mortality rates in UK Biobank, aetiological findings from UK Biobank appear to be generalisable to England and Scotland. This suggests that studies with exceptionally low response rates, conducted at scale and with a range of exposures, have scientific value.

3

Introduction

Well-designed prospective cohort studies have considerable utility in identifying genetic and environmental risk factors for an array of somatic and psychiatric disorders. In the numerous contexts where randomised controlled trials are not feasible, cohort studies provide the best approximation of causality. While deeply-phenotyped studies have existed for decades, recent technological advances have led to low-cost, high-throughput methods to quantify genetic variation which, together with simultaneously expanding prospects for linkage to electronic health and care registries, have made possible the formulation of cohort studies with the capacity to explore gene-environment combinations at previously unheralded scale. Several countries have either established such national 'biobanks', ^{1,2} are in the process of data collection, ³⁻⁵ or are planning such an endeavour. ⁶

One such leading resource is the UK Biobank, an open-access, prospective cohort study comprising over 500,000 middle- and older-aged people. Since the completion of baseline data collection in 2010, use has been high, with the study already yielding over 800 peer-reviewed publications. While UK Biobank is rare in its combination of size, and breadth and depth of content, it has an unusually low response to its baseline survey: of over nine million individuals sent an invitation to participate, only 5.5% did so. This achieved response rate was in part driven by the cost- and time-saving decision not to re-contact undecided individuals. The project came in under-budget and ahead of schedule.

Whereas such an approach is procedurally efficient, the long-held view is that epidemiological studies need to achieve response rates as high as 80% if their findings are to be credible. Vigorous debates about the impact of non-response on estimations of chronic disease determinants in UK Biobank, its primary objective, have ensued. Concerns seem to rest on the assumption that, relative to a more representative study, the recently reported more favourable prevalence of selected risk factors and mortality rates in UK Biobank relative to surveys with a higher response will necessarily affect the generalisability of findings for risk factor—disease associations. The principal investigators of UK Biobank have consistently maintained that, provided the exposures of interest are sufficiently varied and

the sample suitably large, the generalisability of risk factor-health outcome relationships is assured. 11,25,26

To address this central issue of whether risk factors for health outcomes are generalisable in UK Biobank, we directly compare effect estimates for risk factors known to be linked to major causes of mortality with those from a pooling of raw data from 18 nationally-sampled cohort studies drawn from England and Scotland, all of which have a response proportion within the conventional range. With UK Biobank data being deployed across a range of scientific disciplines, we chose an array of mortality endpoints and exposures. Given the nature of our research question, our focus was not on uncovering new risk factors for these health endpoints, rather, testing risk factor—endpoint associations that are well-established based on very strong observational and/or experimental evidence. We therefore examined demographic, social, behavioural, and biomedical risk factors for cardiovascular disease, 29,30 in addition to physical stature in relation to cardiovascular disease and cancer. 31-33 and educational attainment and suicide risk. 34-37

Methods

We used individual-level data from both UK Biobank, a prospective cohort study, and a pooling of eighteen cohort studies with identical core protocols – the Health Survey for England (HSE; 15 studies) and the Scottish Health Surveys (SHS; 3 studies) (hereafter, HSE-SHS). ^{28,38,39} The sampling and procedures of these studies have been well described. ^{7,40} In brief, in UK Biobank, baseline data collection took place between 2006 and 2010 in 22 research assessment centres across the UK, resulting in a sample of 502,655 people aged 40 to 69 years (response rate 5.5%). In HSE and SHS, a total of 193,842 people aged 16-102 years (response rate 68%; range 58-93⁴¹) participated in home-based data collection between 1994 and 2008. ⁴⁰ Analyses of HSE-SHS were, however, limited to 89,895 people (48,364 women) to match the baseline age range in UK Biobank. In UK Biobank, ethical approval was received from the North-West Multi-centre Research Ethics Committee, and the research was carried out in accordance with the Declaration of Helsinki of the World Medical Association. In HSE-SHS, ethical approval for data collection was granted by the London Research Ethics Council, or local research ethics councils. Participants in both studies gave informed consent.

Assessment of baseline characteristics

In both UK Biobank and HSE-SHS, physician-diagnosis of chronic disease (diabetes, hypertension, cardiovascular disease), use of multivitamins, lipid-, blood glucose-, and blood pressure-lowering drugs, educational attainment, cohabitation status, and cigarette smoking habit were self-reported based on identical or near-identical enquiries. Although physical activity and alcohol intake were collected using somewhat different questions, we harmonised data across studies and derived comparable binary categories (current non-drinker versus the rest; physically inactive versus the rest).

During medical examinations, waist and hip circumference, height and weight were measured directly using standard protocols. Elevated waist: hip ratio was denoted by ≥0.90 for men and ≥0.85 for women;⁴² obesity was indicated by a body mass index of ≥30kg/m².⁴³ Forced expiratory volume in one second, a measure of pulmonary function, was quantified using spirometry with the best of three (UK Biobank) or five (HSE-SHS) technically satisfactory blows used. In UK Biobank, seated systolic and diastolic blood pressure measurements were made twice using the Omron HEM-7015IT digital blood pressure monitor (Omron Healthcare)²⁰ or, exceptionally, a manual sphygmomanometer (6652 people). An average of the two readings was used herein. In HSE-SHS, three readings were taken using the Dinamap 8100 automated device,⁴⁴ and a mean of the second and third values was used. We defined hypertension according to existing guidelines as systolic/diastolic ≥140/90 mmHg and/or use of antihypertensive medication.⁴⁵ Non-fasting venous blood was drawn in both studies.^{46,47} Assaying took place at dedicated central laboratories for C-reactive protein, glycated haemoglobin, and total and high-density lipoprotein cholesterol.^{40,46}

Ascertainment of cause-specific mortality

Participants in both studies were linked to mortality records using the procedures of the UK National Health Service Central Registry. Underlying cause of death, coded according to the tenth revision of the International Classification of Disease, was extracted from death certificate data.⁴⁸ We generated the

following mortality outcomes: cardiovascular disease, all cancers combined, lung cancer, smoking—attributable cancers, obesity-attributable cancers, and suicide. The ICD codes denoting these causes of death are given in supplemental table 1.

Statistical analyses

Hazard ratios and accompanying 95% confidence intervals were computed using Cox regression models⁴⁹ and adjusted for age and sex. In these survival analyses we censored individuals according to the date of death or the end of follow-up (14^{th} February 2011 in HSE, 31^{st} December 2009 in SHS; 22^{nd} February 2016 for UK Biobank) – whichever came first. To quantify the difference between the hazard ratios in each of the two studies we computed a ratio of the hazard ratio as we have in other contexts⁴⁸ (UK Biobank was the referent), and calculated the p-value for difference using Fisher's Z score, with Z calculated as the difference between the logarithms of the two study hazard ratios, divided by the square root of the sum of their variances where Z follows a normal distribution ($Z=[\beta 1-\beta 2]/\sqrt{[SE1^2+SE2^2]})$.⁵⁰ Analyses were conducted using Stata version 15.

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. CRG had full access to UK Biobank data and SB had full access to HSE-SHS data. GDB takes responsibility for the decision to submit for publication.

Results

In **table 1** (biomedical factors) and **supplemental figure 1** (demographic, social, and behavioural factors) we compare the baseline characteristics of participants in UK Biobank with those in the pooling of the 18 HSE-SHS cohorts. UK Biobank study members were less likely to have had a below-university level education, to be living alone or unmarried, to be sedentary, have existing cardiovascular disease, or to be taking pharmacological treatments for raised blood glucose, although the reverse was seen for lipid- and blood pressure-lowering medications. In analyses restricted to study members not reporting the use of

such therapies, there was essentially no difference between studies members for total and high-density lipoprotein cholesterol, and glycosylated haemoglobin. Whereas values for C-reactive protein were marginally lower in UK Biobank, both systolic and diastolic blood pressure were somewhat higher.

Taken together, there was a generally more favourable risk factor profile in UK Biobank study members.

In UK Biobank, there were 14,288 deaths during an average of 7.0 years of follow up in 499,701 people consenting to be linked to mortality registers. In the pooling of data from HSE-SHS, 10 years of mortality surveillance gave rise to 7,861 deaths in 89,895 individuals. Of the five mortality categories examined, there were markedly lower rates of cardiovascular disease, all cancers combined, and tobacco-and obesity-attributable cancers in UK Biobank, whereas the rate of suicide was higher (supplemental Table 2).

In figure 1, for each dataset, we depict the direction and strength of the relationship of baseline demographic and behavioural characteristics known to be associated with cardiovascular disease mortality. All well-established risk factors for cardiovascular disease were recapitulated in the present analyses of both studies. The expected direction of association was the same in both studies for the seven characteristics, whereby being male, of higher age, being physically inactive, a non-drinker of alcohol, not being married/cohabiting, a current or former smoker, and not having a higher education degree were related to elevated rates of cardiovascular disease mortality. There was, however, a difference in the magnitude of these effects in four of the risk factors examined, and in most of these the hazards ratios were higher in UK Biobank. When we explored the links between biomedical factors and cardiovascular disease mortality (figure 2), again, all ten of the biomarkers studied revealed known associations with cardiovascular disease deaths in both studies. There was also some heterogeneity in the strength of these relationships for higher levels of glycosylated haemoglobin, existing cardiovascular disease (stronger effects in UK Biobank than HSE-SHS for both risk factors) and hypertension (the reverse).

Nest, we examined the association of selected baseline factors with some non-cardiovascular mortality

outcomes, including different presentations of cancer and also suicide deaths (**figure 3**). These known risk factors were replicated across both studies. The magnitude of the association of cigarette smoking with lung cancer and malignancies aetiologically linked with tobacco were weaker for UK Biobank, whereas obesity and obesity-attributed cancers yielded similar associations in each study. Hazard ratios were also essentially the same for lower educational attainment and suicide although statistical power was modest in these analyses as evidenced by the wide confidence intervals, particularly for HSE-SHS. Physical stature revealed the predicted opposing and shallow gradients for cardiovascular disease (negative) and cancer (positive); again, effect sizes were very similar in both studies.

In sensitivity analyses, we explored the impact of using the same calendar period of study induction in both UK Biobank and HSE-SHS – whereas baseline in UK Biobank was in fact 2006-2010, the latest survey for which we have linked data in the HSE-SHS collaboration was 2008. Results of these subgroup analyses had little impact on our overall conclusions (**supplemental figure 2**). The only obvious anomaly was for obesity which might be explained by the small number of cardiovascular disease deaths. We also examined if results from survival analyses featuring cardiovascular disease as our outcome of interest differed across studies in gender-specific analyses for demographic and behavioural characteristics (**supplemental figure 3**), and biomarkers (**supplemental figure 4**). There was no suggestion of this being the case. Lastly, given that there was, as described, a higher use of medication for blood pressure- and lipid-lowering in members of UK Biobank relative to our comparator cohorts, we tested if this was also evident for other health-seeking behaviours such as vitamin and mineral supplementation. The prevalence of such use was in fact lower in UK Biobank (21.8%) than HSE-SHS (33.1%).

Discussion

Our main finding was that in a comparison of findings between UK Biobank and a pooling of 18 studies from the HSE-SHS consortium, well-established risk factor-mortality associations were recapitulated.

While these effects estimates were directionally consistent between studies there was some difference in

magnitude. This general similarity of results was apparent despite the response rate in UK Biobank being an order of magnitude lower than comparator cohorts, and UK Biobank members having a generally more favourable prevalence of sociodemographic, behavioural, and health characteristics at baseline, and lower rates of cause-specific mortality during follow-up.

Findings from other studies

The only other analyses of risk factor–disease relationships in UK Biobank against comparison studies of which we are aware is that for venous thromboembolism in the Emerging Risk factors Collaboration, a pooling of data from 76 cohort studies.⁵¹ The goal of that paper was risk factor discovery as opposed to testing well-established associations between risk factors and chronic disease. Inter-study comparison was further hampered by differing endpoint ascertainment and blood-based biomarkers from UK Biobank not being available at the time of analyses.

As described, UK Biobank investigators, while acknowledging their study has little value in describing the current prevalence of a risk factor or a disorder – never a stated objective – have attempted to minimise unease around the investigation of chronic disease aetiology – its primary purpose – by arguing that generalisable associations with risk factors can be obtained in non-representative samples provided there are sufficiently large numbers of individuals with a range of exposures. They cite, as circumstantial evidence, examples of cohort studies drawing on highly selected populations that have markedly high response rates than UK Biobank – Framingham residents, British physicians, Sus nurses all of which produced results that have subsequently been shown to be transportable to general population-based studies and have contributed much to the prevention of cardiovascular disease and selected cancers. Similarly, our present findings mirror those from analyses where we have compared risk factors for coronary heart disease in another very select group, a cohort of British civil servants (the Whitehall II prospective cohort study), with those from a cohort based on the general population (the British Regional Heart Study). In those analyses we found near-identical risk factor–disease association across studies.

Strengths and limitations

The strengths of the present study include the comparison of UK Biobank with well-characterised and geographical representative studies that have high response rates. Our report inevitably has some limitations, however. First, whereas UK Biobank includes people from the contiguous countries that comprise the UK, there were no data from Wales in the comparator studies. Second, whereas core elements of data collection in the HSE-SHS consortium were constant across studies, scientific themes for data collection differed from year to year. As such, selected biomedical data were not collected in all cohorts and the analytical sample size was therefore lower for selected analyses. Third, for two variables – physical activity and alcohol intake – baseline data were not directly comparable between studies, though we were able to harmonise data into binary groups. Lastly, although blood samples have been frozen in HSE-SHS, so raising the potential for later genome sequencing, comparison with genetic risk prediction of chronic disease in UK Biobank are currently not possible.

In conclusion, the finding that UK Biobank reveals similar risk factor—mortality associations to those evident in comparator studies with conventional response rates would appear to challenge the prevailing view of a lack of generalisability of aetiological findings in this cohort. This suggests that the cost- and time-savings resulting from its low response rate did not impact upon scientific utility.

References

- 1. Nagai A, Hirata M, Kamatani Y, et al. Overview of the BioBank Japan Project: Study design and profile. *J Epidemiol* 2017; **27**(3s): S2-s8.
- 2. Chen Z, Lee L, Chen J, et al. Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). *Int J Epidemiol* 2005; **34**(6): 1243-9.
- 3. Leitsalu L, Haller T, Esko T, et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *Int J Epidemiol* 2015; **44**(4): 1137-47.
- 4. Cronin RM, Jerome RN, Mapes B, et al. Development of the Initial Surveys for the All of Us Research Program. *Epidemiology* 2019; **30**(4): 597-608.
- 5. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* 2016; **70**: 214-23.
- 6. Al Kuwari H, Al Thani A, Al Marri A, et al. The Qatar Biobank: background and methods. *BMC Public Health* 2015; **15**: 1208.
- 7. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; **12**(3): e1001779.
- 8. Conroy M, Sellors J, Effingham M, et al. The advantages of UK Biobank's open access strategy for health research. *J Intern Med* 2019.
- 9. UK Biobank. Published papers (https://www.ukbiobank.ac.uk/published-papers/ accessed 26th July 2019). 2019.
- 10. Allen N, Sudlow C, Downey P, et al. UK Biobank: Current status and what it means for epidemiology. *Health Policy Techn* 2012; **1**(3): 123-6.
- 11. Manolio TA, Collins R. Enhancing the feasibility of large cohort studies. *JAMA* 2010; **304**(20): 2290-1.
- 12. Evans SJ. Good surveys guide. BMJ 1991; **302**(6772): 302-3.
- 13. Fincham JE. Response rates and responsiveness for surveys, standards, and the Journal. *Am J Pharm Educ* 2008; **72**(2).
- 14. Swanson JM. The UK Biobank and selection bias. Lancet 2012; 380(9837): 110.
- 15. Rothman KJ, Gallacher JE, Hatch EE. Why representativeness should be avoided. *Int J Epidemiol* 2013; **42**(4): 1012-4.
- 16. Elwood JM. Commentary: On representativeness. Int J Epidemiol 2013; 42(4): 1014-5.
- 17. Nohr EA, Olsen J. Commentary: Epidemiologists have debated representativeness for more than 40 years--has the time come to move on? *Int J Epidemiol* 2013; **42**(4): 1016-7.
- 18. Richiardi L, Pizzi C, Pearce N. Commentary: Representativeness is usually not necessary and often should be avoided. *Int J Epidemiol* 2013; **42**(4): 1018-22.
- 19. Ebrahim S, Davey SG. Commentary: Should we always deliberately be non-representative? *Int J Epidemiol* 2013; **42**(4): 1022-6.
- 20. Rothman KJ, Gallacher JE, Hatch EE. Rebuttal: When it comes to scientific inference, sometimes a cigar is just a cigar. *Int J Epidemiol* 2013; **42**(4): 1026-8.
- 21. Richiardi L, Pizzi C, Pearce N. Representativeness. Int J Epidemiol 2014; 43(2): 632-3.
- 22. Rothman K, Hatch E, Gallacher J. Representativeness is not helpful in studying heterogeneity of effects across subgroups. *Int J Epidemiol* 2014; **43**(2): 633-4.
- 23. Keyes KM, Westreich D. UK Biobank, big data, and the consequences of non-representativeness. *Lancet* 2019; **393**(10178): 1297.
- 24. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol* 2017; **186**(9): 1026-34.
- 25. Collins R. What makes UK Biobank special? *Lancet* 2012; **379**(9822): 1173-4.
- 26. Littlejohns TJ, Sudlow C, Allen NE, Collins R. UK Biobank: opportunities for cardiovascular research. *Eur Heart J* 2017.
- 27. Russ TC, Stamatakis E, Hamer M, Starr JM, Kivimaki M, Batty GD. Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. *BMJ* 2012; **345**: e4933.

- 28. Batty GD, Russ TC, Stamatakis E, Kivimaki M. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. *BMJ* 2017; **356**: i108.
- 29. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; **364**(9438): 937-52.
- 30. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001; **104**(22): 2746-53.
- 31. Batty GD, Shipley MJ, Gunnell D, et al. Height, wealth, and health: an overview with new data from three longitudinal studies. *Econ Hum Biol* 2009; **7**(2): 137-52.
- 32. Lee CM, Barzi F, Woodward M, et al. Adult height and the risks of cardiovascular disease and major causes of death in the Asia-Pacific region: 21,000 deaths in 510,000 men and women. *Int J Epidemiol* 2009; **38**(4): 1060-71.
- 33. Stefan N, Haring HU, Hu FB, Schulze MB. Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications. *Lancet Diabetes Endocrinol* 2016; **4**(5): 457-67.
- 34. Batty GD, Kivimaki M, Bell S, et al. Psychosocial characteristics as potential predictors of suicide in adults: an overview of the evidence with new results from prospective cohort studies. *Transl Psychiatry* 2018; **8**(1): 22.
- 35. Li Z, Page A, Martin G, Taylor R. Attributable risk of psychiatric and socio-economic factors for suicide from individual-level, population-based studies: a systematic review. *Soc Sci Med* 2011; **72**(4): 608-16.
- 36. Iemmi V, Bantjes J, Coast E, et al. Suicide and poverty in low-income and middle-income countries: a systematic review. *Lancet Psychiatry* 2016; **3**(8): 774-83.
- 37. Jee SH, Kivimaki M, Kang HC, Park IS, Samet JM, Batty GD. Cardiovascular disease risk factors in relation to suicide mortality in Asia: prospective cohort study of over one million Korean men and women. *Eur Heart J* 2011; **32**(22): 2773-80.
- 38. Mindell J, Biddulph JP, Hirani V, et al. Cohort profile: the health survey for England. *International journal of epidemiology* 2012; **41**(6): 1585-93.
- 39. Gray L, Batty GD, Craig P, et al. Cohort profile: the Scottish health surveys cohort: linkage of study participants to routinely collected records for mortality, hospital discharge, cancer and offspring birth characteristics in three nationwide studies. *International journal of epidemiology* 2010; **39**(2): 345-50.
- 40. Mindell J, Biddulph JP, Hirani V, et al. Cohort profile: the health survey for England. *Int J Epidemiol* 2012; **41**(6): 1585-93.
- 41. McCartney G, Russ TC, Walsh D, et al. Explaining the excess mortality in Scotland compared with England: pooling of 18 cohort studies. *J Epidemiol Community Health* 2015; **69**(1): 20-7.
- 42. Organization WH. Waist circumference and waist-hip ratio Report of a WHO Expert Consultation, Geneva, 8-11 December 2008. Geneva: World Health Organization; 2008.
- 43. Organisation WH. Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. Who Tech. Rep. Ser. Geneva: WHO; 1995.
- 44. Bolling K. The Dinamap 8100 Calibration Study. London: Her Majesty's Stationery Office 1994.
- 45. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *Jama* 2003; **289**(19): 2560-72.
- 46. Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. *Int J Epidemiol* 2008; **37**(2): 234-44.
- 47. Russ TC, Hamer M, Stamatakis E, Starr JM, Batty GD, Kivimaki M. Does the Framingham cardiovascular disease risk score also have predictive utility for dementia death? An individual participant meta-analysis of 11,887 men and women. *Atherosclerosis* 2013; **228**(1): 256-8.
- 48. Batty GD, Gale CR, Kivimaki M, Bell S. Assessment of Relative Utility of Underlying vs Contributory Causes of Death. *JAMA Open Network* 2019.
- 49. Cox D. Regression models and life-tables. J R Stat Soc [Ser B] 1972; 34: 187-220.

- 50. Paternoster R, Brame R, Mazerolle P, Piquero A. Using the correct statistical test for the equality of regression coefficients. *Criminology* 1998; **36**(4): 859-66.
- 51. Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular Risk Factors Associated With Venous Thromboembolism. *JAMA Cardiol* 2019; **4**(2): 163-73.
- 52. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. *American journal of public health and the nation's health* 1957; **47**(4 Pt 2): 4-24.
- 53. Doll R, Bradford Hill A. The mortality of doctors in relation to their smoking habits: a preliminary report. 1954. *BMJ* (*Clinical research ed*) 2004; **328**(7455): 1529-33; discussion 33.
- 54. Colditz GA. The nurses' health study: a cohort of US women followed since 1976. *J Am Med Womens Assoc* 1995; **50**(2): 40-4.
- 55. Batty GD, Shipley M, Tabak A, et al. Generalizability of occupational cohort study findings. *Epidemiology* 2014; **25**(6): 932-3.
- 56. Andersson TM, Weiderpass E, Engholm G, et al. Avoidable cancer cases in the Nordic countries The impact of overweight and obesity. *Eur J Cancer* 2017; **79**: 106-18.
- 57. US Department of Health Human Services. The health consequences of smoking—50 years of progress: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease ...; 2014.
- 58. Batty GD, Kivimaki M, Gray L, Davey Smith G, Marmot MG, Shipley MJ. Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study. *Ann Oncol* 2008; **19**(5): 996-1002.

Table 1. Summary of baseline biomedical characteristics in UK Biobank and the HSE-SHS cohort studies

	UKBB	HSE-SHS
Number of studies	1	18
Number of adults (women)	502,655 (273,472)	89,895 (48,364)
Age, mean (SD), years	56.5 (8.10)	53.5 (8.6)
FEV1, mean (SD), litres	2.81 (0.80)	2.89 (0.89)
Total cholesterol, mean (SD), mmol/L	5.89 (1.07)	5.95 (1.14)
High-density lipoprotein cholesterol, median (IQR), mmol/L	1.43 (1.20-1.71)	1.40 (1.20-1.70)
Glycosylated haemoglobin, median (IQR), mmol/mol	35.0 (32.6-37.4)	36.6 (33.3-40.9)
C-reactive protein, median (IQR), mg/L	1.26 (0.63, 2.49)	1.50 (0.70, 3.10)
Systolic blood pressure, mean (SD), mmHg	137.7 (19.3)	133.3 (18.4)
Diastolic blood pressure, mean (SD), mmHg	81.6 (10.6)	76.6 (11.5)

In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables. Analyses for total cholesterol and high-density lipoprotein excludes participants taking lipid-lowering medication; analyses for glycosylated haemoglobin excludes self-reported diabetics and people taking blood glucose-lowering medication; analyses for C-reactive protein excludes people with values >10 mg/L; and analyses for blood pressure excludes people taking blood pressure-lowering medication. FEV1, forced expiratory volume in one second; IQR, interquartile range; and SD, standard deviation.

Figure 1. Association of baseline demographic and behavioural characteristics with cardiovascular disease mortality in UK Biobank and the HSE-SHS cohort studies

	N	Deaths		HR (95% CI)	RHR (95% CI)	P diff
Male sex						
UK Biobank	502655	2251	•	3.78 (3.42, 4.17)	1.70 (1.48, 1.96)	< 0.001
HSE-SHS	89895	1596	•	2.22 (2.00, 2.46)		
Physically ina	ctive					
UK Biobank	495497	2162	•	3.40 (3.04, 3.80)	1.46 (1.22, 1.75)	< 0.001
HSE-SHS	56703	933	+	2.33 (2.02, 2.68)		
Current non-	drinker					
UK Biobank	501152	2240	+	1.94 (1.72, 2.20)	1.22 (1.01, 1.48)	0.04
HSE-SHS	89845	1592	+	1.59 (1.38, 1.83)		
Not married	cohabiting					
UK Biobank	455597	2038	•	2.22 (2.02, 2.43)	1.17 (1.02, 1.35)	0.02
HSE-SHS	89837	1588	•	1.89 (1.71, 2.10)		
Ever cigarett	e smoker					
UK Biobank	499701	2224	•	2.04 (1.87, 2.24)	1.02 (0.88, 1.19)	0.76
HSE-SHS	89766	1592	•	1.99 (1.78, 2.23)		
Age (per 5 yea	ır increase)					
UK Biobank	502655	2251	•	1.65 (1.59, 1.70)	0.91 (0.87, 0.95)	< 0.001
HSE-SHS	89895	1596	•	1.81 (1.75, 1.88)		
Less than uni	versity edu	cation				
UK Biobank	492513	2167	•	1.59 (1.44, 1.77)	0.83 (0.69, 1.01)	0.06
HSE-SHS	89844	1593	-	1.91 (1.59, 2.31)		
			 	П		


Hazard ratios are age- and sex-adjusted with the exception of age and sex which are mutually adjusted. The shaded diamonds indicate the hazard ratio (HR) and error bars denote the 95% confidence interval (CI) for the relation of each characteristics with the risk of death outcome. The ratio of hazard ratio (RHR) summarises the difference (HSE-SHS is the referent group) between that effect estimates for the outcome, and the p-value is to determine if the observed differences between groups are significant. In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables.

Figure 2. Association of baseline biomedical characteristics with cardiovascular disease mortality in UK Biobank and the HSE-SHS cohort studies

	N	Deaths			HR (95% CI)	RHR (95% CI)	P diff
HbAlc (per o	doubling in 1	mmol/mol)					
UK Biobank	442130	1593		 →	3.86 (3.18, 4.69)	1.95 (1.22, 3.12)	0.01
HSE-SHS	20895	218		-	1.98 (1.29, 3.02)		
Self-reporte	d CVD						
UK Biobank	500431	2240		+	4.92 (4.50, 5.39)	1.89 (1.69, 2.11)	< 0.001
HSE-SHS	89871	1596		•	2.61 (2.35, 2.90)		
Obesity							
UK Biobank	499589	2204		•	1.68 (1.55, 1.83)	1.14 (0.99, 1.32)	0.06
HSE-SHS	82656	1411		+	1.47 (1.31, 1.64)		
Elevated wai	ist:hip rati	0					
UK Biobank	502655	2251			1.88 (1.69, 2.09)	1.12 (0.86, 1.47)	0.39
HSE-SHS	56513	875		-	1.67 (1.31, 2.14)		
Self-reporte	d diabetes	:					
UK Biobank	500038	2233			3.73 (3.38, 4.12)	1.09 (0.91, 1.31)	0.36
HSE-SHS	89871	1596		+	3.43 (2.96, 3.96)		
FEVI (per 0.5	litres/seco	ond)					
UK Biobank	453836	1765	•		0.69 (0.67, 0.72)	1.02 (0.91, 1.15)	0.71
HSE-SHS	26742	629	•		0.68 (0.64, 0.72)		
Total cholest	t erol (per l	l mmol/L in	icrease)				
UK Biobank	387923	1074		ļ	1.01 (0.96, 1.07)	0.98 (0.89, 1.08)	0.62
HSE-SHS	30946	477		•	1.04 (0.96, 1.12)	,	
C-reactive p	rotein (per	r doubling i	n mg/L)				
UK Biobank	449141	1859	0 /		1.30 (1.25, 1.35)	0.95 (0.85, 1.07)	0.41
HSE-SHS	19475	220		•	1.36 (1.23, 1.52)	,	
HDL-cholest	t erol (per d	doubling in	mmol/L)				
UK Biobank	354782	995	-		0.51 (0.42, 0.62)	0.91 (0.66, 1.26)	0.58
HSE-SHS	25951	323	-		0.56 (0.43, 0.72)	, , , , , , , , , , , ,	
Hypertensio	n						
UK Biobank	494047	2179			1.89 (1.69, 2.11)	0.74 (0.62, 0.89)	0.001
HSE-SHS	57116	1002		+	2.56 (2.20, 2.98)	,,,	
			25	1 1 1 1			
			.25	1 2 3 4	3		

Hazard ratios are age- and sex-adjusted. The shaded diamonds indicate the hazard ratio (HR) and error bars denote the 95% confidence interval (CI) for the relation of each characteristics with the risk of death outcome. The ratio of hazard ratio (RHR) summarises the difference (HSE-SHS is the referent group) between that effect estimates for the outcome, and the p-value is to determine if the observed differences between groups are significant. The distributions of glycosylated haemoglobin (HbA1c), C-reactive protein, and HDL-cholesterol were skewed, hence they were \log_2 -transformed and effect estimates reflect a doubling in the biomarker. Elevated waist: hip ratio was denoted by ≥ 0.90 for men and ≥ 0.85 for women; obesity was indicated by a body mass index of ≥ 30 kg/m². CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; HDL, high-density lipoprotein. In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables

Figure 3. Association of selected baseline characteristics with cause-specific mortality in UK Biobank and the HSE-SHS cohort studies



Hazard ratios are age- and sex-adjusted. The shaded diamonds indicate the hazard ratio (HR) and error bars denote the 95% confidence interval (CI) for the relation of each characteristics with the risk of death outcome. The ratio of hazard ratio (RHR) summarises the difference (HSE-SHS is the referent group) between that effect estimates for the outcome, and the p-value is to determine if the observed differences between groups are significant. Analyses for education were based on less than university education versus the rest; a body mass index of \geq 30 kg/m² for obesity; and a per 5 cm increase in height. In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables.

Supplemental Table 1. Mortality outcomes in the present analyses

Mortality outcome	ICD 10 codes
All cancers combined	C00-C97
Obesity-attributable cancers ⁵⁶	Breast (postmenopausal) C50; Colon C18; Rectum C19-20;
	Pancreas C25; Endometrium C54; Kidney C64; Ovary C56
	& C57.0–4; Multiple myeloma C90; Liver C22; Thyroid
	C73; Gallbladder C23-24; Oesophageal adenocarcinoma
	C15 & morphology 8140–8141, 8143–8145, 8190–8231,
	8260–8263, 8310,8401, 8480–8490, 8550–8551, 8570–
	8574, 8576; and Gastric cardia C16.0
Smoking-attributable cancers ^{57,58}	Lip, oral cavity, pharynx C00–C14, oesophagus C15,
	stomach C16, colon and rectum C18–C20, liver C22,
	pancreas C25, larynx C32, trachea, lung, bronchus C33–
	C34, cervix uteri C53, kidney and renal pelvis C64–C65,
	urinary bladder C67, and acute myeloid leukemia C92.0
Cardiovascular disease	I20-5, I50, I60-70, I73, I74
Suicide ³⁴	Suicide and self-inflicted poisoning by solid or liquid
	substances (E950-E959), injury undetermined whether
	accidentally or purposely inflicted (E980-E989), terrorism
	(U03.1 and U03.9), intentional self-harm (X60-X84), event
	of undetermined intent (Y10-Y34), sequelae of intentional
	self-harm, assault and events of undetermined intent (Y87),
	and sequelae of unspecified external cause (Y89.9))
Lung cancer	C34


Supplemental Table 2. Mortality rates in participants in UK Biobank and the HSE-SHS cohort studies

	UKBB	HSE-SHS
Number of adults (women)	502,655	89,895
	(273,472)	(48,364)
Duration of mortality surveillance (years, mean [SD])	6.99 (1.03)	9.62 (4.39)
Total number of deaths	14,288	7,861
Mortality rate for cardiovascular disease	64	185
Mortality rate for all cancers combined	236	342
Mortality rate for tobacco-attributable cancers	120	198
Mortality rate for obesity-attributable cancers	94	132
Mortality rate for suicide	6	4

Mortality rates are per 100,000 person-years. Analyses are based on 502,655 people in UK Biobank and 89,895 in HSE-SHS. SD, standard deviation.

20

Supplemental Figure 1. Prevalence of baseline characteristics in UK Biobank and the HSE-SHS cohort studies*



^{*}Selected comparisons have been published by Fry and others²⁴ using published results from four HSE studies (2006, 2008, 2009, and 2010). Our analyses are based on analyses of raw data from 18 cohort studies from England and Scotland which include two of those HSE studies (2006, 2008). Analyses comprise 502,655 people in UK Biobank and 89,895 in HSE-SHS. BMI, body mass index; CVD, cardiovascular disease.

Supplemental Figure 2. Association of selected baseline characteristics with cardiovascular disease mortality in UK Biobank and the HSE-SHS cohort studies – analyses based on the same survey years (2006-08)

	N	Death	s		HR (95% CI)	RHR (95% CI)	P diff
Male sex							
UK Biobank (2006-08)	240895	1328		+	3.75 (3.31, 4.26)	1.11 (0.57, 2.16)	0.76
HSE (2006-08)	14828	47		 →	3.38 (1.75, 6.51)		
Physically inactive							
UK Biobank (2006-08)	235633	1257		+	3.22 (2.78, 3.74)	1.45 (0.68, 3.07)	0.34
HSE (2006-08)	12012	37			2.23 (1.07, 1.65)		
Current non-drinker							
UK Biobank (2006-08)	240353	1321		+	1.82 (1.54, 2.14)	0.90 (0.39, 2.04)	0.79
HSE (2006-08)	14825	47			2.03 (0.90, 4.55)		
Not married/cohabiting							
UK Biobank (2006-08)	219830	1195		+	2.12 (1.88, 2.39)	0.87 (0.48, 1.59)	0.66
HSE (2006-08)	14827	47		-	2.43 (1.35, 4.37)		
Ever cigarette smoker							
UK Biobank (2006-08)	239677	1310			2.06 (1.83, 2.32)	0.91 (0.18, 1.81)	0.85
HSE (2006-08)	11816	17			2.20 (1.11, 1.27)		
Age (per 5 year increase)							
UK Biobank (2006-08)	240895	1328			1.68 (1.61, 1.75)	0.89 (0.71, 1.11)	0.29
HSE (2006-08)	14828	47		-	1.89 (1.52, 2.35)		
Less than university educ	ation						
UK Biobank (2006-08)	234291	1260		+	1.61 (1.40, 1.85)	0.17 (0.02, 1.22)	0.08
HSE (2006-08)	14826	47		│	9.67 (1.33, 70.35)		
Self-reported CVD							
UK Biobank (2006-08)	240078	1320)	5.02 (4.46, 5.64)	1.86 (1.02, 3.41)	0.04
HSE (2006-08)	14826	47			2.69 (1.49, 4.87)		
Obesity							
UK Biobank (2006-08)	239612	1305			1.70 (1.52, 1.90)	2.36 (1.15, 4.87)	0.02
HSE (2006-08)	13466	41	-	⊢	0.72 (0.35, 1.47)	,	
Elevated waist:hip ratio							
UK Biobank (2006-08)	240895	1328			1.97 (1.72, 2.25)	0.39 (0.12, 1.25)	0.11
HSE (2006-08)	11966	37			5.04 (1.59, 15.98)	()	
Self-reported diabetes							
UK Biobank (2006-08)	239932	1315			3.67 (3.22, 4.19)	1.60 (0.73, 3.49)	0.24
HSE (2006-08)	14826	47		-	2.29 (1.06, 4.95)	(
Hypertension							
UK Biobank (2006-08)	235045	1267		+	1.92 (1.66, 2.22)	0.69 (0.28, 1.67)	0.41
HSE (2006-08)	9499	30			2.78 (1.16, 6.65)	0.07 (0.20.1.01)	V. 11
				<u> </u> 			
				1 2 3 4 5			

Hazard ratios are age- and sex-adjusted with the exception of age and sex which are mutually adjusted. The shaded diamonds indicate the hazard ratio (HR) and error bars denote the 95% confidence interval (CI) for the relation of each characteristics with the risk of death outcome. The ratio of hazard ratio (RHR) summarises the difference (HSE-SHS is the referent group) between that effect estimates for the outcome, and the p-value is to determine if the observed differences between groups are significant. Elevated waist: hip ratio was denoted by ≥ 0.90 for men and ≥ 0.85 for women; obesity was indicated by a body mass index of ≥ 30 kg/m². CVD, cardiovascular disease. In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables.

Supplemental Figure 3. Association of baseline demographic and behavioural characteristics with cardiovascular disease mortality in UK Biobank and the HSE-SHS cohort studies – stratification by gender

			Men							Wome	en		
	N	Deaths		HR (95% CI)	RHR (95% CI)	P diff		N	Deaths		HR (95% CI)	RHR (95% CI)	P diff
Physically in	active						Physically	inactive					
UK Biobank	225912	1655	+	3.40 (2.99, 3.88)	1.52 (1.15, 2.00)	0.003	UK Biobar	k 269585	507	→	3.34 (2.69, 4.15)	1.42 (1.07, 1.87)	0.01
HSE-SHS	30648	340	-	2.24 (1.76, 2.86)			HSE-SHS	26055	593	+	2.36 (1.99, 2.80)		
Current non	-drinker						Current	on-drinker					
UK Biobank	228421	1716	+	1.81 (1.55, 2.11)	1.03 (0.80, 1.32)	0.84	UK Biobar	k 272731	524	-	2.21 (1.79, 2.73)	1.55 (1.16, 2.08)	0.003
HSE-SHS	48332	563	-	1.76 (1.44, 2.15)			HSE-SHS	41513	1029	-	1.42 (1.16, 1.74)		
Not married	l/cohabitin	g					Not man	ied/cohabiti	ng				
UK Biobank	213476	1573	•	2.43 (2.19, 2.70)	1.37 (1.13, 1.67)	0.002	UK Biobar	k 242121	465	-	1.61 (1.33, 1.95)	0.82 (0.65, 1.04)	0.10
HSE-SHS	48333	563	+	1.77 (1.50, 2.09)			HSE-SHS	41504	1025	+	1.96 (1.72, 2.24)		
Ever cigaret	te smoker						Ever ciga	rette smoke	r				
UK Biobank	227749	1704	•	2.06 (1.85, 2.29)	1.03 (0.84, 1.27)	0.74	UK Biobar	k 271952	520	-	2.06 (1.73, 2.45)	1.02 (0.81, 1.28)	0.88
HSE-SHS	48319	564	+	1.99 (1.67, 2.36)			HSE-SHS	41447	1028	+	2.02 (1.74, 2.35)		
Age (per 5 ye	ar increase)						Age (per	year increase	e)				
UK Biobank	229183	1724	•	1.60 (1.54, 1.66)	0.83 (0.77, 0.89)	< 0.001	UK Biobar	k 273472	527		1.83 (1.70, 1.97)	1.04 (0.96, 1.13)	0.34
HSE-SHS	48364	566	•	1.93 (1.81, 2.05)			HSE-SHS	41531	1030	•	1.76 (1.68, 1.83)		
Less than un	iversity ed	lucation					Less than	university e	ducation				
UK Biobank	224391	1659	•	1.54 (1.37, 1.72)	0.73 (0.50, 1.08)	0.11	UK Biobar	k 268122	508	-	1.82 (1.44, 2.32)	0.98 (0.71, 1.36)	0.90
HSE-SHS	48337	565	-	2.09 (1.45, 3.01)			HSE-SHS	41507	1028	-	1.86 (1.49, 2.32)		
		.25	1 2 3 4						.25	1 2 3 4			

Hazard ratios are age- and sex-adjusted. The shaded diamonds indicate the hazard ratio (HR) and error bars denote the 95% confidence interval (CI) for the relation of each characteristics with the risk of death outcome. The ratio of hazard ratio (RHR) summarises the difference (HSE-SHS is the referent group) between that effect estimates for the outcome, and the p-value is to determine if the observed differences between groups are significant. In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables.

Supplemental Figure 4. Association of baseline biomedical characteristics with cardiovascular disease mortality in UK Biobank and the HSE-SHS cohort studies – stratification by gender

				Men			
	N	Deaths		HR (95%	CI)	RHR (95% CI)	P diff
HbAlc (per d	doubling in r	mmol/mol)					
UK Biobank	198688	1191		→ 3.94 (3.20,		1.01 (0.49, 2.09)	0.98
HSE-SHS	11200	78		→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→	7.82)		
Self-reported	d CVD						
UK Biobank	228109	1714		→ 4.90 (4.43,	5.42)	1.93 (1.57, 2.37)	< 0.001
HSE-SHS	48352	566		→ 2.54 (2.12,	3.03)		
Obesity							
UK Biobank	227562	1689		◆ 1.76 (1.60,	1.94)	1.32 (1.07, 1.63)	0.01
HSE-SHS	44206	500		→ 1.33 (1.10,	1.60)		
UK Biobank	229183	1724		→ 1.89 (1.66,	2.15)	1.12 (0.82, 1.54)	0.47
HSE-SHS	30317	298		1.68 (1.26,		,	
Self-reported UK Biobank	d diabetes 227770	1710		 → 3.55 (3.18, 	3 97)	0.71 (0.54, 0.92)	0.01
HSE-SHS	48352	566		→ 5.02 (3.97,		0.71 (0.54, 0.72)	0.01
FEVI (per 0.5		,					
UK Biobank HSE-SHS	205164 14171	1345 212	•	0.70 (0.68, 0.57 (0.50,		1.23 (1.08, 1.41)	0.002
H3E-3H3	14171	212	•	0.37 (0.30,	0.04)		
Total cholest	terol (per l	mmol/L incre	ase)				
UK Biobank	165632	767		0.99 (0.92,	,	0.91 (0.78, 1.05)	0.20
HSE-SHS	16680	165		1.09 (0.96,	1.25)		
C-reactive p	rotein (per	doubling in n	ng/L)				
UK Biobank	206473	1419		◆ I.34 (I.29,	,	1.03 (0.85, 1.25)	0.75
HSE-SHS	10261	68		1.30 (1.07,	1.57)		
HDL-cholest	erol (per d	loubling in mn	nol/L)				
UK Biobank	152947	719	+	0.58 (0.47,	0.72)	1.33 (0.82, 2.17)	0.25
HSE-SHS	14071	107 -	•	0.43 (0.28,	0.67)		
Hypertensio	n						
UK Biobank	224588	1656		→ 1.89 (1.65,	2.15)	0.64 (0.47, 0.86)	0.003
HSE-SHS	30881	345		2.95 (2.26,	3.86)		
		_		 			
		.25		1 2 3 4 5			

Hazard ratios are age- and sex-adjusted. The shaded diamonds indicate the hazard ratio (HR) and error bars denote the 95% confidence interval (CI) for the relation of each characteristics with the risk of death outcome. The ratio of hazard ratio (RHR) summarises the difference (HSE-SHS is the referent group) between that effect estimates for the outcome, and the p-value is to determine if the observed differences between groups are significant. HbA1c, glycosylated haemoglobin; FEV1, forced expiratory volume in one second; and HDL, high-density lipoprotein. In both studies, the sample size is the maximum number with baseline data; numbers are lower for selected variables.